Table III.
Animal model used to exhibit the effectiveness of vaccines against SARS-CoV-2 infection
| Vaccine type | Design strategy | Animal model | Reference |
|---|---|---|---|
| DNA vaccine | Full length and truncated forms of SARS-CoV-2 Spike gene | Rhesus macaques | 58 |
| Vector (ChAdOx1 nCoV-19) | Adenovirus vector expressing SARS-CoV-2 Spike protein | Rhesus macaques and mice | 59 |
| Inactivated virus | Undisclosed | Rhesus macaques | 60 |
| RNA vaccine | SARS-CoV-2 S gene mRNA encapsulated in nanoparticle | Rhesus macaques and mice | 61,62 |
| Inactivated virus | Inactivation of virus using β-propiolactone | Rhesus macaques, mice and rats | 63 |
| DNA vaccine (INO-4800) | Construct with SARS-CoV-2 S gene | Mice and guinea pigs | 64 |